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INTRODUCTION
The use of high-dose therapy and autologous stem cell
transplantation has become standard therapy for many
patients with lymphoma. Unfortunately, the majority of
patients who undergo this procedure are destined to relapse
[1,2]. The causes of relapse include residual neoplastic cells
persisting in the patient despite high-dose therapy and rein-
troduction of malignant cells into the host with the stem cell
graft. Whereas the relative contributions of each factor to
relapse are unknown, both have been implicated [3]. Strate-
gies are needed to address both problems. The upper limit of
dose escalation in the preparative regimens has already been
reached. Because of mechanisms of action that are not cross-
resistant with chemotherapy, immunotherapy with monoclo-
nal antibodies has the potential to affect both of these factors.
Antibody purging of bone marrow with autologous
transplantation is effective in follicular lymphomas. Gribben
et al. [4] demonstrated that successful purging of a marrow
graft with monoclonal antibodies in vitro is associated with
improved disease-free survival. The efﬁcacy of the marrow
purge was assessed by polymerase chain reaction (PCR) of
marrow specimens before and after the purge. Detection of
residual lymphoma cells in marrow after purging was associ-
ated with a 39% relapse rate after a median follow-up of
23 months versus a 5% relapse rate in patients whose mar-
rows showed no residual lymphoma (P < .00001).
Treating a patient with a tumor-specific monoclonal
antibody before collecting the stem cells may be one way of
reducing the number of lymphoma cells contaminating the
peripheral blood and may, in effect, purge the stem cell graft
in vivo. Similarly, using a non–cross-resistant immunother-
apy, administering an antibody after transplantation at a
time of minimal residual disease may increase the efﬁcacy of
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ABSTRACT
Peripheral blood stem cell grafts from patients with lymphoma are often contaminated with neoplastic cells. Admin-
istration of a lymphoma-specific monoclonal antibody before collecting stem cells may be one way of reducing the
contamination. Similarly, an antibody after transplantation at a time of minimal residual disease may increase the effi-
cacy of the procedure. The objective of this study was to determine the safety of using rituximab as both an in vivo
purging agent and a posttransplantation adjuvant. Eligible patients with lymphoma received 375 mg/m2 rituximab
intravenously (IV) on day 1, 2.5 g/m2 cyclophosphamide IV on day 4, and 10 µg/kg per day filgrastim starting on day 5
and continuing until completion of leukapheresis. Patients subsequently received a standard preparative regimen and
then received 375 mg/m2 rituximab IV 7 days after platelet independence was achieved. Twenty-five patients
(14 men, 11 women; median age, 51 years) were enrolled. Of the 25 patients, 23 received transplants after at least
2.0  106 CD34+ cells/kg were harvested. As determined with a sensitive polymerase chain reaction assay, 6 of 7 stem
cell products tested were free of tumor contamination. All patients engrafted promptly, and the rituximab infusions
were well tolerated. Transient neutropenia of uncertain etiology occurred in 6 patients a median of 99.5 days post-
transplantation. An additional patient developed progressive pancytopenia. Rituximab used as an in vivo purging
agent and adjuvant immunotherapy with peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma is a
well-tolerated regimen. However, the ultimate determination of efficacy will require the results of ongoing studies. 
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the procedure. Rituximab is an immunoglobulin (Ig) G1-
chimeric mouse/human antibody containing murine light-
and heavy-chain variable regions and human -1 heavy-
chain and light-chain constant regions [5]. The antibody
reacts speciﬁcally with the CD20 antigen on the surface of
malignant and normal B cells and established B-cell lines
[6,7]. Rituximab binds human C1q and effects both comple-
ment-mediated and antibody-dependent cell-mediated lysis
of antigen-positive cells [5]. In vitro experiments show that
the antibody induces apoptosis [8]. Speciﬁcally, the antibody
sensitizes drug-resistant human B-cell lymphoma cell lines
to the cytotoxic effects of cisplatin, VP-16, and ricin [9] and
may overcome drug resistance. The antibody depletes B cells
from the peripheral blood, lymph nodes, and bone marrow
[10] beginning after the ﬁrst dose. The antibody does not
deplete bone marrow progenitors in the presence of human
complement, because uncommitted hematopoietic precur-
sor stem cells do not express CD20 [11]. Based on both the
preclinical data and preliminary data from clinical trials
indicating the efﬁcacy of rituximab in indolent lymphoma,
the current study was undertaken to evaluate the toxicity
and efﬁcacy of rituximab as both an in vivo purging agent
and a posttransplantation adjuvant.
PATIENTS AND METHODS
Eligibility Criteria
Twenty-ﬁve patients with biopsy-proven low- or inter-
mediate-grade non-Hodgkin’s indolent lymphoma (noncon-
tiguous stage IIa or greater) were entered into this protocol,
which was approved by the Institutional Review Board of the
Johns Hopkins Hospital. Patients with the following histolo-
gies that express the CD20 antigen were eligible: follicular
center cell lymphoma (grades I-III), B-cell chronic lympho-
cytic leukemia/small lymphocytic lymphoma, lymphoplasma-
cytic lymphoma, mantle cell lymphoma, and marginal zone
lymphoma (including nodal monocytoid B-cell lymphoma
and low-grade mucosa-associated lymphoid tissue). Patients
were men or nonpregnant women (the latter conﬁrmed by
negative results of a serum pregnancy test) at least 18 years of
age and, if of childbearing potential, practicing an effective
means of contraception. Patients were to be free of active
infection and to have adequate renal function (serum creati-
nine, ≤2.0 mg/dL), hepatic function (total bilirubin,
≤2 mg/dL), and hematologic function (white blood cell
count [WBC], ≥3000/mm3; platelet count, ≥100  109/L).
Patients were required to have a forced expiratory volume in
1 second (FEV1) and forced vital capacity (FVC) ≥ 50% of
normal if the patients had not had thoracic or mantle irradia-
tion. Patients who had received thoracic or mantle irradia-
tion were required to have an FEV1 and FVC ≥ 75% of nor-
mal. Patients had adequate cardiac function (left ventricular
ejection fraction, ≥45% by multiple-gated acquisition scan or
normal echocardiogram), an Eastern Cooperative Oncology
Group performance status of ≤2, and an expected survival of
≥12 weeks. Bone marrow had lymphoma in ≤10% of the
nucleated cells at study entry. Patients with other malignan-
cies (except nonmelanoma skin cancer or carcinoma in situ of
the cervix) were excluded. Written informed consent was
obtained from all patients before inclusion in the study.
Study Design and Treatment Plan
Stem Cell Mobilization. Patients received 375 mg/m2 rit-
uximab intravenously (IV) over 4 to 8 hours and then
72 hours later received 2.5 g/m2 cyclophosphamide IV over
1 hour. Mesna (500 mg/m2) was administered IV 30 minutes
before and 3, 6, and 8 hours after cyclophosphamide adminis-
tration. Patients were administered saline IV at a rate sufﬁ-
cient to maintain a urine output of 1.5 mL/kg per hour.
Patients also received an appropriate anti-emetic regimen.
Filgrastim (granulocyte colony-stimulating factor [G-CSF])
(Neupogen; Amgen, Thousand Oaks, CA) was administered
subcutaneously (SC) at 10 µg/kg per day starting on the day
after chemotherapy and continuing until completion of leuka-
pheresis. Patients received prophylaxis with ciprofloxacin
(500 mg po BID) for 10 days starting on day 5 after chemo-
therapy. Daily measurements of WBC were begun on day 7
(typically the nadir of WBC), and daily CD34 counts were
obtained when the WBC reached 1000. Leukapheresis began
when the peripheral blood CD34 count was ≥10/µL. Stem
cell collection was performed by high-volume apheresis
(35-50 L per session) using a COBE Spectra apheresis
machine (Gambro BCT, Lakewood, CO) via a large-bore
double-lumen catheter for venous access. CD34 counts were
measured by ﬂow cytometry. A goal of 5  106 CD34+ cells/kg
was set. Patients were required to have 2  106 CD34+
cells/kg to proceed to transplantation.
High-Dose Therapy. All but 1 patient received
cyclophosphamide (50 mg/kg per day IV for 4 days) and
total body irradiation (300 cGy/day for 4 days, anterior pos-
terior/posterior anterior at 9.6 cGy/min using photons from
a 4-MV linear accelerator) as the preparative regimen for
peripheral blood stem cell transplantation (PBSCT) [12].
One patient (number 2875) had received primary radiother-
apy for her disease and thus received busulfan (16 mg/kg po
over 4 days) and cyclophosphamide (50 mg/kg per day IV
for 4 days) as the preparative regimen [13]. The entire
leukapheresis product was infused into patients on day 0 of
the transplantation regimen.
Posttransplantation Supportive Care and Immunother-
apy. Patients received standard antibiotic prophylaxis and
supportive care [14] and were administered G-CSF (5 µg/kg
per day SC) starting on day 1 and continuing until the
absolute neutrophil count (ANC) was ≥1000/µL for 3 days
or until day 30. Patients were discharged from the inpatient
unit when the ANC was ≥500/µL. Two patients underwent
PBSCT as outpatients and were admitted only for complica-
tions such as neutropenic fever. Patients received a second
dose of 375 mg/m2 rituximab IV after engraftment, which
was deﬁned as having an ANC of ≥1000 for 3 days and an
unsupported platelet count of ≥20,000 for 7 days.
Evaluation of Purging. Samples of the graft were evalu-
ated for contamination with lymphoma using PCR for the
14:18 or 11:14 translocations after ﬁrst determining if one of
these translocations was detectable in tissue from a previous
diagnostic biopsy. Diagnostic tissue from patients with either
follicular or mantle cell lymphoma and aliquots of frozen
PBSC samples were shipped on dry ice to IMPATH/BIS
Laboratories (Los Angeles, CA) or PCR analysis. The
mononuclear cell fraction was thawed in a water bath (37°C)
with DNase (Sigma Chemical, St. Louis, MO) and washed
twice in Leibovitz L-15 medium (Gibco, Grand Island, NY)
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containing DNase. Tumor tissue obtained from slides was
homogenized. The DNA from tissue or mononuclear cells
was extracted and isolated using standard methods. PCR was
used to detect major break points (MBR) for the 11:14 (bcl-1)
and the 14:18 (bcl-2) translocations [15,16] by subjecting
200 ng genomic DNA to 35 cycles of ampliﬁcation. Ampli-
ﬁed product DNA (4 µL) was hybridized with the 5 end of
32P-radiolabeled oligonucleotide probes to MBR at 55°C.
The hybridized product was loaded onto an 8% polyacryla-
mide gel electrophoresis gel, and autoradiography was per-
formed for 18 hours. To ensure reliability of the PCR assay, a
positive and negative control were included in each run. In a
parallel run, 200 ng -globulin was run to conﬁrm the pres-
ence of amplified DNA. The sensitivity of this assay was
approximately 1/100,000.
Response Criteria. Patients achieving a complete regres-
sion of all palpable and x-ray demonstrable disease and bone
marrow disease judged by iliac crest bone marrow biopsy (if
initially positive) were considered to have had a complete
response (CR). Lymph nodes remaining in areas of previous
known disease were considered to be uninvolved if they
measured 1.0  1.0 cm and if they were not of abnormal
consistency on palpation. Lymph nodes of larger size must
have been documented to be free of tumor on biopsy if a
patient was to be considered a complete responder. If the
liver or spleen was enlarged before onset of treatment, it
must have returned to normal size.
Patients who did not achieve a CR but who showed a
response to therapy with a ≥50% reduction in the sum of
the products of the dimensions of the measurable lesions
were considered to have a partial response (PR).
Disease that did not satisfy the criteria of CR or PR was
categorized as no change. Stable disease was also deﬁned by
at least a 4-week period that ﬁt that description. Progressive
disease was deﬁned as an increase in size of 25% of the sum
of the products of the pretreatment measurements or
appearance of new lesions. Relapse was deﬁned as the reap-
pearance of any clinical evidence of lymphoma in a patient
who had a CR. Relapse for partial responders was deﬁned as
progressive disease relative to disease status during the par-
tial remission.
Statistics. The primary end points of this study were
measures of safety: the ability to mobilize adequate stem
cells for transplantation and the number of patients for
whom engraftment failed after stem cell transplantation.
The ability to collect stem cells was measured by the num-
ber of patients from whom 2  106 CD34+ cells/kg were
collected. A sample size of 25 patients was chosen to achieve
an 87% power ( = 0.05) to differentiate between harvest
failure rates of 20% and 45%. Adequate engraftment was
deﬁned by 90% of patients reaching engraftment for neu-
trophils by day 28 and platelets by day 35. A sample size of
25 patients provides 87% power and a type 1 error of 3%
with respect to differentiating between nonengraftment
event rates of 5% and 25%.
RESULTS
Patient Population
A total of 25 patients were entered in the study. All were
considered to have sensitive disease. The majority were men
(56%), all were Caucasian, and the median age was 51 years
(range, 33-67 years) (Table 1). The patients’ diagnoses are
listed in Table 1. All patients had received at least 1 previous
regimen of chemotherapy (median 1, range 1-3). Fourteen
patients had been treated with fludarabine or fludarabine
and cyclophosphamide, and 14 had received cyclophos-
phamide, doxorubicin, vincristine, and prednisone (CHOP).
Most patients were in their ﬁrst CR or PR. Twelve patients
were in CR at time of study entry. Five patients had mor-
phologic evidence of bone marrow involvement but no evi-
dence of disease on computed tomography (CT) scans,
whereas 3 patients had residual disease detectable by CT but
no evidence of lymphoma on bone marrow examination.
Five patients had residual disease detectable by both bone
marrow examination and CT scans.
Mobilization, Graft Content, and Engraftment
Of the 25 patients, 23 achieved at least the required
minimum of 2.0  106 CD34+ cells/kg. The stem cell graft
for these patients contained a median 1.07  107 CD34+
cells/kg (range, 2.51  106 to 5.95  107 CD34+ cells/kg).
The 2 patients who failed to adequately mobilize both had
prior treatment with fludarabine. Eighteen of 23 patients
required only 1 high-volume apheresis to achieve adequate
harvest. Diagnostic specimens in patients with adequate tis-
sue available from a previous biopsy and who had either fol-
licular or mantle cell lymphoma were evaluated for t(11:14)
or t(14:18). Seven patients had either t(11:14) or t(14:18)
detectable by PCR in diagnostic tissue. These translocations
were not detectable in 6 of 7 of the stem cell grafts (Table 2)
after in vivo purging. Four of the 7 patients were in com-
plete remission at the time of entry into the protocol. Two
had normal CT scans but had morphologic evidence of
bone marrow involvement. The remaining patient did not
meet CT criteria for CR and had no marrow involvement at
the time of entry into the study.
Engraftment was rapid. Neutrophil recovery (ANC,
≥1000) occurred at a median of day 10 (range, 7-15 days).
Platelet engraftment (unsupported platelet count, ≥20,000)
occurred at day 9 (range, 3-14 days).
Table 1. Characteristics of 25 Patients With Non-Hodgkin’s Indolent
Lymphoma*
Age, y 51 (33-67)
Sex, M:F 14:11
Status at trial entrance
First complete remission 12
First partial remission 6
Second partial remission 5
Third partial remission 2
Histology
Follicular center cell 11
Mantle cell 7
CLL/SLL 5
Lymphoplasmacytic 1
Marginal zone 1
Number of prior therapies 1 (1-3)
*Data are median (range) or n. CLL/SLL indicates chronic lym-
phocytic leukemia/small lymphocytic lymphoma. 
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Responses
The 23 patients who received high-dose therapy were
evaluated for response. Eleven patients were considered to be
in complete remission at the time of transplantation. All
patients were considered to have chemotherapy-sensitive
lymphoma, deﬁned as at least a 50% decrease in the sum of
the perpendicular measurements of sentinel lymph nodes
after the last chemotherapy regimen. Of the 12 patients, 11
not in CR at the time of transplantation were evaluated at
approximately 60 days posttransplantation: 6 patients achieved
CR, 3 achieved PR, and 2 patients had stable disease.
Toxicity
Toxicities related to rituximab were primarily infusion-
related and mild. During the pretransplantation infusion, 10 of
25 patients developed fever, chills, or hypotension, which
required either temporarily slowing or stopping the infusion.
All patients received the entire infusion. Posttransplantation,
3 of 23 patients developed infusion-related symptoms, which
required the slowing or interruption of rituximab. The infu-
sion-related reactions posttransplantation occurred in
2 patients who had a reaction to the infusion pretransplanta-
tion and 1 patient who had not previously reacted.
There were no clinically signiﬁcant infections, deﬁned
as either a positive culture or clinical or radiographic evi-
dence of infection, within the ﬁrst 60 days posttransplanta-
tion in any of the patients. Late infectious complications
included localized herpes zoster infection in 3 patients. One
patient developed inﬂuenza A and made a full recovery with
only symptomatic support.
Within a median follow-up of 240 days, 1 patient died of
multisystem organ failure. This patient had prompt initial
engraftment from a stem cell graft that contained 2.51  106
CD34+ cells/kg but developed the slow onset of cytopenias
starting at approximately day 30. The neutrophils were ini-
tially responsive to ﬁlgrastim; however, the patient eventually
developed pancytopenia and died on day 232. No cause for the
graft failure was determined despite extensive investigation
including viral cultures. Six patients developed transient neu-
tropenia (ANC, <500) a median of 99.5 days posttransplanta-
tion. Systematic evaluation of these patients was not possible
because they were being treated by their referring oncologist.
However, 4 of the patients had a febrile illness most consistent
with a viral infection simultaneously with the onset of the neu-
tropenia. Bone marrow evaluations at the 6-month posttrans-
plantation visit revealed generally hypocellular marrow with
normal trilinear hematopoiesis consistent with the recent stem
cell transplant. In all patients, this neutropenia resolved spon-
taneously or with ﬁlgrastim. One patient developed idiopathic
thrombocytopenia starting at day 42 with numerous mega-
karyocytes noted on bone marrow biopsy. The thrombocy-
topenia resolved with a short course of corticosteroids and has
not recurred at more than 1 year of follow-up.
One patient developed mild dementia ﬁrst noted approxi-
mately 11 months after transplantation. Extensive neurologic
evaluation, magnetic resonance imaging, electroencephalo-
gram, and lumbar puncture failed to reveal a deﬁnitive cause.
The presumptive diagnosis was late ﬂudarabine toxicity possi-
bly exacerbated by the high-dose preparative regimen.
Immune Reconstitution
No CD19+ B cells were detected in the peripheral blood
of 12 of 19 patients 6 months after transplantation. At the
6-month posttransplantation evaluation, the absolute num-
ber of CD4+ T cells (median, 186/mL) and serum levels of
IgG (median, 603 mg/dL) and IgM (median, 28.5 mg/dL)
were below the reference ranges (absolute CD4+ reference
range, 458-1344/mL; IgG reference range, 690-1620 mg/dL;
and IgM reference range, 60-260 mg/dL).The median
serum IgA level (71.5 mg/dL) was at the very low end of the
reference range of 70 to 380 mg/dL. The median absolute
number of CD8+ T cells (577/mL) was within the reference
range of 107 to 2448 T cells/mL.
DISCUSSION
High-dose therapy and autologous stem cell transplanta-
tion has become standard therapy for many patients with
non-Hodgkin’s lymphoma. Unfortunately, the stem cell graft
is often contaminated with malignant cells. As standard prac-
tice, many centers purge autologous stem cell grafts ex vivo
with a variety of methods, including monoclonal antibodies
or chemotherapeutic drugs, or attempt to decrease lym-
phoma contamination using positive selection techniques
[4,11,17,18]. These approaches are cumbersome, require
signiﬁcant technical expertise, and are not universally avail-
able. We have demonstrated that in vivo purging with ritux-
imab for CD20+ malignancies is a feasible alternative. This
approach does not interfere with mobilization. In the limited
number of patients tested, purging with rituximab provided a
stem cell graft in which lymphoma contamination was below
our level of detection, consistent with previous data that rit-
uximab rapidly depletes the peripheral blood of B cells. In
addition, in vivo purging is a simple approach that should be
achievable in all transplant centers. Whereas monoclonal
antibodies have been available for many years, in vivo purg-
ing was not possible until the development of humanized
monoclonal antibodies that react with human effector cells.
Despite receiving a lymphoma-free stem cell graft,
many patients will ultimately relapse with their lymphoma.
Adjuvant therapy after engraftment is an area of active
investigation. We have demonstrated that immunotherapy
with rituximab can be delivered safely in the majority of
patients shortly after engraftment at a time when there is
minimal residual disease.
The toxicity of this regimen appeared to be signiﬁcantly
less than that of many other purging methods [11]. The eti-
ology of transient neutropenia is uncertain. Whereas it was
associated with what was described as viral infections in
Table 2. Evaluation of Stem Cell Grafts With Polymerase Chain Reaction
for Known Translocations
Patient Number Translocation Contamination of Graft
2837 14:18 Negative
2869 14:18 Negative
2897 11:14 Positive
2938 14:18 Negative
2944 11:14 Negative
2981 14:18 Negative
2994 14:18 Negative
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most cases, we cannot exclude autoimmune causes. We have
previously noted a decrease in neutrophil counts occurring
between 60 and 100 days posttransplantation, usually in
recipients of allogeneic grafts [19]. In the patients in this
trial, the neutropenia did not result in any signiﬁcant infec-
tions. The progressive pancytopenia occurring in 1 patient
is also of uncertain etiology. In the autologous setting, graft
failure is a rare event that is usually associated with a viral
infection. No infection was identiﬁed in this patient.
Delayed immune reconstitution is a potential concern
when using this approach. B-cell reconstitution clearly had
not occurred by 6 months; there is often little B-cell recon-
stitution at this point after transplantation [20]. The level of
immunoglobulin depression seen in this trial is of uncertain
clinical signiﬁcance. Rituximab does not bind mature plasma
cells. However, both high-dose therapy and anti-CD20
monoclonal antibodies deplete plasma cell precursors. Ulti-
mately, infectious complications will be more important
than absolute levels of immunoglobulins and B cells in
determining the toxicity proﬁle of this regimen. To date, we
have not seen an increase in infectious events with this
approach. However, long-term follow-up is needed. Fur-
thermore, whereas this regimen appears relatively safe, its
ultimate utility awaits further data on the regimen’s true
purging capability as well as the important clinical end
points of overall and disease-free survival.
Numerous questions remain regarding the use of ritux-
imab in transplantations—many stemming from funda-
mental questions about the mechanism or mechanisms of
action of the antibody. We chose to give 1 dose of ritux-
imab before cyclophosophamide in the mobilization regimen
to take advantage of the reported synergy of rituximab
with chemotherapy [9]. One might choose a different
schedule and dose if the mechanism of action was predom-
inantly mediated through antibody-dependent cellular
cytotoxicity rather than through the induction of apopto-
sis. Similarly, we elected to give the posttransplantation
adjuvant dose shortly after hematopoietic reconstitution.
Delivering the antibody at a time of minimal residual dis-
ease and before reconstitution with normal CD20+ cells is
appealing, but the efficacy of the antibody may be
decreased if antibody-dependent cellular cytotoxicity is a
significant mechanism of action for this antibody. We are
currently addressing this issue by attempting to augment
the number and function of immune effector cells post-
transplantation. Data from ongoing laboratory studies and
clinical trials in the nontransplantation setting may be use-
ful in the design of future transplant trials.
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